---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-115139"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:39:38.934338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics Q4/FY2025 net loss $19M/$77.9M; cash $118.6M; ACR-368 52% cORR in serous EC

## Summary
- Net loss Q4 $19.0M, FY $77.9M; cash and securities $118.6M expected to fund into Q2 2027.
- ACR-368 Phase 2b showed 52% confirmed ORR in serous endometrial cancer; Arm 3 enrolling, Arm 4 to start H1 2026.
- Completed exploratory Arm 2 (ACR-368 + ULDG) in biomarker-negative EC; objectives met with favorable tolerability.
- ACR-2316 Phase 1 data shows tumor shrinkage in SCLC and squamous NSCLC; IND for ACR-6840 planned Q4 2026.
- Launched wholly-owned CLIA lab for companion diagnostic development.

## SEC filing metadata
- accession: 0001193125-26-115139
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526115139/0001193125-26-115139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526115139/acrv-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-115139
- JSON: https://secwatch.observer/filing/0001193125-26-115139.json
- Plain text: https://secwatch.observer/filing/0001193125-26-115139.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.